Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Lead Product(s) : Methotrexate,Adalimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Methotrexate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 10, 2013
Lead Product(s) : Adalimumab,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Uveitis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : Adalimumab,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Fully Human Anti-TNFα Monoclonal Antibody HUMIRA® Obtains Additional Approval for High-Dose Regi...
Details : HUMIRA® is a fully human anti-TNF-α monoclonal antibody, got additional approval for a highdose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients.
Product Name : Humira
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 27, 2021
Lead Product(s) : Adalimumab,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HUMIRA (adalimumab) is the first and only subcutaneous biologic treatment option for pediatric patients from 5 years of age with moderately to severely active ulcerative colitis.
Product Name : Humira
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 24, 2021
Lead Product(s) : Adalimumab,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to ...
Details : Approval for adalimumab based on results from the pivotal Phase 3 ENVISION I study showing the higher dosage of HUMIRA induced clinical remission in 60 percent of patients at Week 8 and 45 percent of patients, who responded at Week 8, were in remission a...
Product Name : Humira
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 24, 2021
Lead Product(s) : Adalimumab,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pyoderma Gangrenosum.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 17, 2017
Lead Product(s) : Adalimumab,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : waqqas.afif
Deal Size : Inapplicable
Deal Type : Inapplicable
TDM Guided Early Optimization of ADAL in Crohn's Disease
Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Crohn Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 24, 2017
Lead Product(s) : Adalimumab,Methotrexate
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Jeffrey J Crowley MD
Deal Size : Inapplicable
Deal Type : Inapplicable
MAP Study: Methotrexate and Adalimumab in Psoriasis
Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 14, 2017
Lead Product(s) : Adalimumab,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa
Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hidradenitis Suppurativa.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 19, 2016
Lead Product(s) : Adalimumab,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : IST GmbH | Hannover Medical School | Improvement by Movement
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Axial Spondyloarthritis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 13, 2016
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Rochem International Inc
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
Dosage Form : Tablet
Grade : Oral
Application : Taste Masking
Excipient Details : Mannitol is used as a filler, bulking agent and taste masking agent in ODT formulations such as tablets.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dr. Paul Lohmann GmbH & Co. KGaA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CD Formulation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gloria Interchem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Fillers, Diluents & Binders
Parenteral
Chewable & Orodispersible Aids
Solubilizers
Direct Compression
Taste Masking
Disintegrants & Superdisintegrants
API Stability Enhancers
Thickeners and Stabilizers
Topical
Co-Processed Excipients
Granulation
Surfactant & Foaming Agents
Emulsifying Agents
Film Formers & Plasticizers
Rheology Modifiers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Annual Reports
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 19,832
2019 Revenue in Millions : 19,169
Growth (%) : 3
Main Therapeutic Indication : Immunology (Organ Transplant, Arthr...
Currency : USD
2017 Revenue in Millions : 18,427
2016 Revenue in Millions : 16,078
Growth (%) : 15
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 20,694
2020 Revenue in Millions : 19,832
Growth (%) : 4
Main Therapeutic Indication : Immunology (Organ Transplant, Arthr...
Currency : USD
2016 Revenue in Millions : 16,078
2015 Revenue in Millions : 14,012
Growth (%) : 15
Main Therapeutic Indication : Immunology (Organ Transplant, Arthr...
Currency : USD
2015 Revenue in Millions : 12,543
2014 Revenue in Millions : 14,012
Growth (%) : 12%
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 21,237
2021 Revenue in Millions : 20,694
Growth (%) : 3
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 14,404
2022 Revenue in Millions : 21,237
Growth (%) : -32
Main Therapeutic Indication : Immunology
Currency : USD
2024 Revenue in Millions : 8,993
2023 Revenue in Millions : 14,404
Growth (%) : -38
Main Therapeutic Indication : Immunology (Organ Transplant, Arthr...
Currency : USD
2018 Revenue in Millions : 19,936
2017 Revenue in Millions : 18,427
Growth (%) : 8%
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 19,169
2018 Revenue in Millions : 19,936
Growth (%) : -4
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
APIs
Reply
26 Aug 2024
Reply
18 Mar 2023
Reply
29 Mar 2022
Reply
18 Jun 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Health Canada Patents
Patent Expiration Date : 2017-02-10
Date Granted : 2002-09-17
Brand Name : HUMIRA
Patent Number : 2243459
Filing Date : 1997-02-10
Strength per Unit : 50 mg / mL (40 mg in 0.8 mL)
Dosage Form : Solution
Human Or VET : Human
Route of Administration : Subcutaneous Injection
Patent Expiration Date : 2017-02-10
Date Granted : 2002-09-17
Patent Expiration Date : 2022-05-10
Date Granted : 2015-02-17
Brand Name : HUMIRA
Patent Number : 2385745
Filing Date : 2002-05-10
Strength per Unit : 50 mg / mL (40 mg in 0.8 mL)
Dosage Form : Solution
Human Or VET : Human
Route of Administration : Subcutaneous Injection
Patent Expiration Date : 2022-05-10
Date Granted : 2015-02-17
Patent Expiration Date : 2023-08-15
Date Granted : 2014-07-22
Brand Name : HUMIRA
Patent Number : 2494756
Filing Date : 2003-08-15
Strength per Unit : 50 mg / mL (40 mg in 0.8 mL)
Dosage Form : Solution
Human Or VET : Human
Route of Administration : Subcutaneous Injection
Patent Expiration Date : 2023-08-15
Date Granted : 2014-07-22
Patent Expiration Date : 2025-04-11
Date Granted : 2015-04-07
Brand Name : HUMIRA
Patent Number : 2847142
Filing Date : 2005-04-11
Strength per Unit : 50 mg / mL (40 mg in 0.8 mL)
Dosage Form : Solution
Human Or VET : Human
Route of Administration : Subcutaneous Injection
Patent Expiration Date : 2025-04-11
Date Granted : 2015-04-07
Patent Expiration Date : 2025-04-11
Date Granted : 2016-11-29
Brand Name : HUMIRA
Patent Number : 2504868
Filing Date : 2005-04-11
Strength per Unit : 50 mg / mL (40 mg in 0.8 mL)
Dosage Form : Solution
Human Or VET : Human
Route of Administration : Subcutaneous Injection
Patent Expiration Date : 2025-04-11
Date Granted : 2016-11-29
Patent Expiration Date : 2025-04-11
Date Granted : 2015-04-07
Brand Name : HUMIRA
Patent Number : 2847142
Filing Date : 2005-04-11
Strength per Unit : 100mg / mL (40mg / 0.4mL)
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 2025-04-11
Date Granted : 2015-04-07
Patent Expiration Date : 2017-02-10
Date Granted : 2002-09-17
Brand Name : HUMIRA
Patent Number : 2243459
Filing Date : 1997-02-10
Strength per Unit : 100mg / mL (40mg / 0.4mL)
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 2017-02-10
Date Granted : 2002-09-17
Patent Expiration Date : 2022-05-10
Date Granted : 2015-02-17
Brand Name : HUMIRA
Patent Number : 2385745
Filing Date : 2002-05-10
Strength per Unit : 100mg / mL (40mg / 0.4mL)
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 2022-05-10
Date Granted : 2015-02-17
Patent Expiration Date : 2031-11-11
Date Granted : 2016-11-22
Brand Name : HUMIRA
Patent Number : 2815689
Filing Date : 2011-11-11
Strength per Unit : 100mg / mL (40mg / 0.4mL)
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 2031-11-11
Date Granted : 2016-11-22
Patent Expiration Date : 2025-04-11
Date Granted : 2016-11-29
Brand Name : HUMIRA
Patent Number : 2504868
Filing Date : 2005-04-11
Strength per Unit : 100mg / mL (40mg / 0.4mL)
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 2025-04-11
Date Granted : 2016-11-29
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Comment (4)
